Tomislav Dragovich

Tomislav Dragovich

Auto-generated profile, based on publicly available information

Tomislav Dragovich

Banner MD Anderson Cancer Center, Gilbert, AZ

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
SKSunilkumar Kakadia
Sunilkumar Kakadia
NYNaveen Yarlagadda
Naveen Yarlagadda
RARamez Awad
Ramez Awad
MKMadappa Kundranda
Madappa Kundranda
JNJiaxin Niu
Jiaxin Niu
FMFade Mahmoud
Fade Mahmoud
Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and encorafenib and binimetinib are US Food and Drug Administration (FDA)-approved to treat patients with BRAFV600-mutated advanced melanoma. Both genetic and epigenetic alterations play a major role in resistance to BRAF inhibitors by reactivation of the MAPK and/or the PI3K–Akt pathways. The role of BRAF inhibitors in modulating the immunomicroenvironment and perhaps enhancing the efficacy of checkpoint inhibitors is gaining interest. This article provides a comprehensive review of mechanisms of resistance to BRAF and MEK inhibitors in melanoma and summarizes landmark trials that led to the FDA approval of BRAF and MEK inhibitors in metastatic melanoma.

20 October 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TDTomislav Dragovich
Tomislav Dragovich
SMSheryl McCoy
Sheryl McCoy
CFCecilia M. Fenoglio-Preiser
Cecilia M. Fenoglio-Preiser
JWJiang Wang
Jiang Wang
JBJacqueline K. Benedetti
Jacqueline K. Benedetti
JAJames L. Abbruzzese
James L. Abbruzzese
Purpose: A phase II trial of the oral epidermal growth factor receptor (EGFR) inhibitor erlotinib in patients with gastroesophageal adenocarcinomas stratified according to primary tumor location into two groups: gastroesophageal junction (GEJ)/cardia and distal gastric adenocarcinomas. Patients and Methods: Patients with a histologically proven diagnosis of adenocarcinoma of the GEJ or stomach (ST) that was unresectable or metastatic; presence of measurable disease; no prior chemotherapy for advanced or metastatic cancer; Zubrod performance status (PS) of 0 to 1; and adequate renal, hepatic, and hematologic function were treated with erlotinib 150 mg/d orally. Patient characteristics were median age, GEJ—63 years, ST—64 years; sex, GEJ—84% male and 16% female, ST—60 male and 40 female; Zubrod PS, GEJ—25 had a PS of 0 and 18 had a PS 1, ST—13 had a PS of 0 and 12 had a PS of 1. Results: Percentage of common toxicities were skin rash, 86% and 72%; fatigue, 51% and 44%; and AST/ALT elevation, 28% and 28%, respectively for GEJ and ST. There has been one confirmed complete response, three confirmed partial responses (PRs) and one unconfirmed PR for an overall response probability of 9% confirmed (95% CI, 3% to 22%), all occurring in GEJ stratum. No responses were observed in ST stratum. The median survival was 6.7 months in GEJ and 3.5 months in ST stratum. Neither intratumoral EGFR, transforming growth factor–alpha or phosphorylated Akt kinase expression nor plasma proteomic analyses were predictive of clinical outcome. No somatic mutations of the EGFR exons 18, 19, or 21 were detected and there was no gross amplification of EGFR by fluorescence in situ hybridization. Conclusion: Erlotinib is active in patients with GEJ adenocarcinomas, but appears inactive in gastric cancers. The molecular correlates examined were not predictive of the patient therapeutic response.

1 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MBMitesh J. Borad
Mitesh J. Borad
SRShantan G. Reddy
Shantan G. Reddy
NBNathan Bahary
Nathan Bahary
HUHope E. Uronis
Hope E. Uronis
DSDarren Sigal
Darren Sigal
DRDavid P. Ryan
David P. Ryan
Purpose: TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer. Patients and Methods: Patients were randomly assigned 1:1:1 to gemcitabine (1,000 mg/m2), gemcitabine plus TH-302 240 mg/m2 (G+T240), or gemcitabine plus TH-302 340 mg/m2 (G+T340). Randomized crossover after progression on gemcitabine was allowed. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), tumor response, CA 19-9 response, and safety. Results: Two hundred fourteen patients (77% with metastatic disease) were enrolled between June 2010 and July 2011. PFS was significantly longer with gemcitabine plus TH-302 (pooled combination arms) compared with gemcitabine alone (median PFS, 5.6 v 3.6 months, respectively; hazard ratio, 0.61; 95% CI, 0.43 to 0.87; P = .005; median PFS for metastatic disease, 5.1 v 3.4 months, respectively). Median PFS times for G+T240 and G+T340 were 5.6 and 6.0 months, respectively. Tumor response was 12%, 17%, and 26% in the gemcitabine, G+T240, and G+T340 arms, respectively (G+T340 v gemcitabine, P = .04). CA 19-9 decrease was greater with G+T340 versus gemcitabine (−5,398 v −549 U/mL, respectively; P = .008). Median OS times for gemcitabine, G+T240, and G+T340 were 6.9, 8.7, and 9.2 months, respectively (P = not significant). The most common adverse events (AEs) were fatigue, nausea, and peripheral edema (frequencies similar across arms). Skin and mucosal toxicities (2% grade 3) and myelosuppression (55% grade 3 or 4) were the most common TH-302–related AEs but were not associated with treatment discontinuation. Conclusion: PFS, tumor response, and CA 19-9 response were significantly improved with G+TH-302. G+T340 is being investigated further in the phase III MAESTRO study (NCT01746979).

24 December 1998 in Oncogene
Verified
Journal Article
Closed access
TDTomislav Dragovich
Tomislav Dragovich
CRCharles M Rudin
Charles M Rudin
CTCraig B Thompson
Craig B Thompson

15 June 2005 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ABAmanda F. Baker
Amanda F. Baker
TDTomislav Dragovich
Tomislav Dragovich
NINathan T. Ihle
Nathan T. Ihle
RWRyan Williams
Ryan Williams
CFCecilia Fenoglio-Preiser
Cecilia Fenoglio-Preiser
GPGarth Powis
Garth Powis
Purpose: The purpose of the study was to evaluate the stability of phosphoprotein as a marker of signaling activity in human tumors using clinical samples and xenografts.

23 May 2006 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
TDTomislav Dragovich
Tomislav Dragovich
DMDavid Mendelson
David Mendelson
SKSandra Kurtin
Sandra Kurtin
KRKelly Richardson
Kelly Richardson
DHDaniel Von Hoff
Daniel Von Hoff
AHAxel Hoos
Axel Hoos